Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.

About the study

The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.

Study point of contact

Robert Swift, PhD
[email protected]
Carolyn O' Reilly, BA
[email protected]


18 Years - 55 Years


Phase 1

Study type






participation requirements

Male or female, 18-55 years of age
Homozygous sickle cell disease or S/beta 0 thalassemia
Hemoglobin F ≤10%
Hemoglobin ≥ 6.0 g/dL and ≤ 9.5 g/dL
Female participants of child bearing potential and male participants whose partner is a female of child bearing potential must be willing to use approved contraception during the trial and for 3 months following the end of treatment. Only barrier methods or complete abstinence are acceptable for this study. Participants using hormonal contraception (including morning-after-pill) and IUD are excluded unless willing/able to change to an acceptable form of contraception.
Ability to adhere to the study visit schedule and other protocol requirements
Ability to understand and the willingness to sign an informed consent document

participation restrictions

Red blood cell transfusion within 3 months of enrollment
Hydroxyurea treatment within 6 months of enrollment
Painful or other acute sickle cell event that required a hospitalization within 4-weeks of enrollment
AST and/or ALT >3x upper limit of normal and/or creatinine >2x upper limit of normal or any other significant renal or hepatic impairment
Estimated creatinine clearance (CrCl) < 60 mL/min (Cockcroft- Gault formula) at screening. QTc interval of >470 msec at trial entry and participant with congenital long QT syndrome.
No other significant sickle cell or non-sickle cell illness that would confound the results of the trial
Any condition that, in the view of the investigator, places the participant at risk because of participation in the trial, or may influence the result of the trial or the participant’s ability to participate in the trial
Participant pregnant or nursing an infant or planning pregnancy during the course of the trial
History of allergic reactions attributed to sorghum or compounds of similar chemical or biologic composition (such as Nicosan, Niprisan, Jobelyn or Xickle).
Other investigational drug use within 3 months of enrollment
PROMIS Fatigue Questionnaire 8a T-score ˂ 44.3

Last updated 2021-02-19